Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
119 hedge funds and large institutions have $647M invested in Esperion Therapeutics in 2017 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 38 increasing their positions, 31 reducing their positions, and 11 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
248% more capital invested
Capital invested by funds: $186M → $647M (+$461M)
236% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 11
23% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 31
20% more funds holding
Funds holding: 99 → 119 (+20)
15.49% more ownership
Funds ownership: 65.72% → 81.22% (+15%)
70% less call options, than puts
Call options by funds: $19.7M | Put options by funds: $66.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$29.3M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$29.2M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$16.1M |
| 4 |
PA
Pinnacle Associates
New York
|
+$15M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aisling Capital
New York
|
-$18.3M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$15.1M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$8.92M |
| 4 |
SAM
Senzar Asset Management
New York
|
-$4.56M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$3.1M |
ESPR Hedge Fund Activity: Q1 2017 in Review
119 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2017, worth a combined $647M — up 248% from $186M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ESPR positions and 11 closed out — a net gain of 26 holders — while 38 added to existing stakes and 31 trimmed.
The largest buyer was BlackRock, adding an estimated $29.3M. The largest seller was Aisling Capital, cutting an estimated $18.3M.
- 119 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2017, up from 99 in Q4 2016.
- Funds reported $647M of Esperion Therapeutics stock for Q1 2017, up 248% quarter-over-quarter.
- 37 funds opened new Esperion Therapeutics positions in Q1 2017 and 11 closed out, a net change of +26 holders.
- The largest Esperion Therapeutics buyer in Q1 2017 was BlackRock, an estimated $29.3M added.
- The largest Esperion Therapeutics seller in Q1 2017 was Aisling Capital, an estimated $18.3M sold.
Based on aggregated 13F filings for Q1 2017.